Portfolio

Amphista Therapeutics

CEO Antony Mattessich

Amphista Therapeutics is a leading European targeted protein degradation (TPD) company.

The company has developed several completely novel mechanisms to remove disease-causing proteins with the potential to overcome many of the limitations seen with current TPD approaches.

Their therapeutics, known as Amphistas, have the potential to deliver transformational medicines to treat a wide range of diseases.

Human Health

Amphista Therapeutics

UK

The Cori Building, Granta Park,
Great Abington,
Cambridge
CB21 6GQ

Industry

Biotech

Status

Current

Location

UK